Ownership history in GROUP ONE TRADING LLC Β· 9 quarters on record
This page tracks every 13F SEC filing in which GROUP ONE TRADING LLC reported a position in RECURSION PHARMACEUTICALS IN (RXRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π GROUP ONE TRADING LLC underperformed the S&P 500 by β61.8% annually on this RXRX position. Timing score: 38% (3/8 decisions correct). Average cost basis: $6.18. Maximum drawdown during holding period: β54.1%.
β Significantly underperformed the S&P 500 by 61.8% ann.
6 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
3 of 8 add/trim decisions correct
Best entry: $4.88 (2025 Q3) Β· Worst: $10.64 (2022 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 2 trims. Bought during 5 of 7 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size